A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations
Clinical trial NCT03226301 · UNKNOWN
Trial details
- NCT number
- NCT03226301
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-23
- Primary completion
- 2021-06-30
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.